LC
SGMO

Lindbrook Capital’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Lindbrook Capital’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,700
Closed -$2.99K – 2838
2023
Q1 		$2.99K Sell
1,700
-1,958
-54% -$5.59K ﹤0.01% 2079
2022
Q4 		$11.5K Buy
3,658
+3,582
+4,713% +$13.9K ﹤0.01% 1370
2022
Q3 		$0 Buy
+76
New +$390 ﹤0.01% 2882
2022
Q2 		– Sell
-89
Closed -$1K – 2739
2022
Q1 		$1K Buy
+89
New +$529 ﹤0.01% 2349
2019
Q4 		– Sell
-150
Closed -$1K – 1544
2019
Q3 		$1K Hold
150
– – ﹤0.01% 1388
2019
Q2 		$1K Buy
+150
New +$1.59K ﹤0.01% 1353

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lindbrook Capital's SGMO Position: Q2 2023 in Review

Lindbrook Capital sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2023, closing a stake of 1,700 shares — an estimated $2.99K sold.

Lindbrook Capital first reported a position in SGMO in Q2 2019 and held it in 6 quarters. The position peaked at $11.5K in Q4 2022. 152 funds tracked by Wall St. Rank hold SGMO as of Q2 2023.

  • Lindbrook Capital reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2023 after selling out during the quarter.
  • Lindbrook Capital sold 1,700 SANGAMO THERAPEUTICS INC shares in Q2 2023, an estimated $2.99K.
  • Lindbrook Capital first reported a position in SANGAMO THERAPEUTICS INC in Q2 2019 and held it in 6 quarters.
  • Lindbrook Capital's SANGAMO THERAPEUTICS INC position peaked at $11.5K in Q4 2022.
  • 152 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2023.

Based on Lindbrook Capital's 13F filing for Q2 2023, filed 31 Jul 2023.